ReviewClinical ophthalmology (Auckland, N.Z.)2020
Blood Biomarkers of Uveal Melanoma: Current Perspectives.
Review in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Precision Oncology in Ocular Melanoma: Integrating Molecular and Liquid Biopsy Biomarkers.Current issues in molecular biology · 2026Review
- Blood-Based Cell-Free DNA in Ophthalmic Oncology.Translational vision science & technology · 2025Review
- Serum gp100 as an Independent Prognostic Biomarker in Early-Stage Uveal Melanoma.Investigative ophthalmology & visual science · 2025Article
- Role of miRNA in adult ocular tumorigenesis.Frontiers in molecular biosciences · 2025Review
- 1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature.Cell death discovery · 2024Article
- The role of circulating tumor DNA in melanomas of the uveal tract.Frontiers in immunology · 2024Review
- Genetic and Epigenetic Features of Uveal Melanoma-An Overview and Clinical Implications.International journal of molecular sciences · 2023Review
- Clinical Applications of Machine Learning in the Management of Intraocular Cancers: A Narrative Review.Investigative ophthalmology & visual science · 2023Review
- Choroidal Melanoma: A Case Series From Malaysia.Cureus · 2022Article
- TRPM4 and TRPV2 are two novel prognostic biomarkers and promising targeted therapy in UVM.Frontiers in molecular biosciences · 2022Article
- Early detection of metastatic uveal melanoma by the analysis of tumor-specific mutations in cell-free plasma DNA.Cancer medicine · 2021Article
- The Role of LncRNAs in Uveal Melanoma.Cancers · 2021Review
- Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.Journal of experimental & clinical cancer research : CR · 2021Article
- Evaluation of a Three-Marker Panel for the Detection of Uveal Melanoma Metastases: A Single-Center Retrospective Analysis.Cancers · 2021Article
- Article
- Emerging roles of microRNAs and their implications in uveal melanoma.Cellular and molecular life sciences : CMLS · 2021Review
- Review
- The Role of Non-Coding RNAs in Uveal Melanoma.Cancers · 2020Review
- Exosomes: Insights from Retinoblastoma and Other Eye Cancers.International journal of molecular sciences · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The detection of metastases in patients with a diagnosis of uveal melanoma (UM) is a controversial issue. While only 1% of the patients have detectable metastases at the time of diagnosis, up to 30% of them will develop liver metastases within 5 years of treatment. UM spreads hematogenously, therefore, blood biomarkers may be helpful for prognosis and monitoring the disease progression. Despite the great progress achieved thanks to the genetic analysis of UM biopsies, this is an invasive technique and is limited by the heterogeneity of the tumor. The present review considers the current understanding in the field regarding biomarkers for the diagnosis and prognosis of UM and its metastasis, primarily to the liver. General covered topics include non-conventional markers such as proteins previously identified in cutaneous melanoma and UM cell lines, circulating tumor cells, microRNAs (miRNA), and circulating DNA, and how each may be critical in the development of novel blood biomarkers for UM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.